2021 World Conference on Lung Cancer (Posters)-P29. Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III

P29. Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III

Back to course

Video Transcription

Video Summary

Jan Wagner, a medical student, presents the results of a study on the prognostic marker of PD-L1 expression after combined radiochemotherapy in NSCLC Stage 3. The study aims to test the hypothesis that PD-L1 expression can be a prognostic factor. The study used clinical data and characteristics from a tumor database, with 99 patients included. The study found that there was no significant difference in overall survival and progress-free survival based on PD-L1 expression. The study suggests that PD-L1 expression may not reliably predict prognosis and recommends further studies with a larger patient collective.

Asset Subtitle

Jan Wagner

Meta Tag

Speaker Jan Wagner

Topic Locally Advanced Non-Small Cell Lung Cancer

Keywords

PD-L1 expression

prognostic marker

combined radiochemotherapy

NSCLC Stage 3

clinical data